neutral
effect
antibodi
target
ctermin
stalk
subunit
spike
protein
sever
acut
respiratori
syndrom
coronaviru
previous
report
although
mechan
remain
elus
studi
high
titer
mous
antisera
ntermin
globular
subunit
protein
gener
total
immunoglobulin
g
igg
purifi
antisera
effici
purifi
igg
viru
neutral
block
receptor
bind
compar
quantit
use
viru
neutral
assay
previous
develop
cellbas
receptor
bind
assay
respect
demonstr
igg
neutral
viru
bind
membran
associ
protein
effici
igg
moreov
igg
abl
abolish
bind
protein
cellular
receptor
although
igg
show
significantli
higher
block
effici
unexpect
block
abil
igg
toward
receptor
bind
impli
possibl
role
subunit
viru
dock
process
argu
current
hypothesi
viral
entri
hand
function
role
previous
report
neutral
epitop
within
subunit
investig
use
antigen
specif
antibodi
deplet
assay
deplet
antibodi
region
significantli
diminish
though
complet
abolish
neutral
effect
igg
suggest
absenc
major
neutral
domain
protein
possibl
way
igg
abolish
receptor
bind
factor
restrict
igg
neutral
viru
discuss
sever
acut
respiratori
syndrom
sar
emerg
infecti
diseas
caus
zoonot
coronaviru
cov
name
sarscov
pandem
reemerg
potenti
diseas
urg
develop
effect
vaccin
viru
base
experi
anim
coronavir
vaccin
develop
recombin
vaccin
sarscov
mainli
focus
spike
glycoprotein
protein
cov
classifi
class
viral
fusion
protein
exist
radial
protrud
trimer
viral
envelop
structur
function
divid
two
subunit
name
subunit
repres
ntermin
globular
head
ctermin
membranebound
stalk
respect
subunit
respons
viru
bind
cellular
receptor
contain
neutral
epitop
subunit
mediat
membran
fusion
viral
infect
believ
unabl
induc
neutral
antibodi
number
cov
contrari
sever
report
suggest
subunit
sarscov
contain
neutral
epitop
viru
immun
either
escherichia
coli
express
chemic
synthes
peptid
elicit
neutral
antibodi
specif
antibodi
respons
anim
model
moreov
neutral
epitop
map
subunit
biopan
phage
display
dodecapeptid
librari
antisera
convalesc
sar
patient
screen
antibodyphag
display
librari
construct
bcell
convalesc
sar
patient
immun
plasmid
encod
subunit
may
better
mimic
nativ
antigen
properti
report
induc
neutral
antibodi
rabbit
earlier
studi
also
demonstr
cooper
neutral
effect
antibodi
mice
immun
plasmid
encod
subunit
result
suggest
presenc
neutral
epitop
within
subunit
sarscov
abbrevi
sar
sever
acut
respiratori
syndrom
sarscov
sar
coronaviru
spike
ntermin
domain
protein
ctermin
domain
protein
igg
immunoglobulin
g
hr
heptad
repeat
chr
ctermin
hr
hiv
human
immunodefici
viru
rad
recombin
adenovirus
ms
membran
associ
atcc
american
type
cultur
collect
gfp
green
fluoresc
protein
n
nucleocapsid
rmva
recombin
modifi
vaccinia
viru
ankara
mfi
mean
fluoresc
intens
histag
histidin
tag
commonli
observ
number
cov
mechan
effici
neutral
effect
antibodi
logic
propos
prevent
spiketoreceptor
engag
event
block
receptor
bind
domain
howev
mechan
involv
neutral
mediat
antibodi
remain
clarifi
class
viral
fusion
protein
subunit
coronavirus
typic
function
domain
includ
fusion
peptid
heptad
repeat
hr
aromat
amino
acid
cluster
transmembran
domain
block
action
involv
domain
may
prevent
viru
enter
host
cell
although
concept
remain
proven
experiment
neutral
antibodi
subunit
mous
hepat
viru
report
bind
determin
nine
amino
acid
near
fusion
peptid
prevent
fusion
activ
viru
entri
lip
colleagu
demonstr
monoclon
antibodi
target
region
within
immedi
ctermin
hr
chr
domain
abl
neutral
sarscov
inhibit
cellcel
membran
fusion
impli
block
membran
fusion
may
possibl
neutral
mechan
antibodi
recent
advanc
epitop
map
human
immunodefici
viru
hiv
membran
anchor
subunit
class
viral
fusion
protein
counterpart
sarscov
subunit
identifi
sever
neutral
epitop
proxim
viral
membran
near
fusion
peptid
although
mechan
neutral
epitop
hiv
well
understood
result
suggest
antibodi
target
membran
anchor
subunit
class
viral
fusion
protein
eg
subunit
sarscov
may
also
effici
interfer
viru
entri
host
cell
although
neutral
effect
antibodi
coronavirus
wide
character
compar
quantit
neutral
mechan
antibodi
still
unclear
studi
immun
mice
plasmid
recombin
adenovirus
rad
encod
subunit
sarscov
viru
neutral
effici
purifi
igg
well
bind
abil
toward
membran
associ
ms
protein
ie
protein
anchor
cell
membran
resembl
nativ
structur
compar
quantit
addit
use
cellbas
receptor
bind
assay
also
show
antibodi
abl
abolish
bind
ms
cellular
receptor
provid
possibl
new
clue
toward
understand
neutral
mechan
antibodi
mammalian
cell
line
includ
stratagen
vero
american
type
cultur
collect
atcc
atcc
atcc
chicken
embryon
fibroblast
cell
line
atcc
propag
maintain
accord
manufactur
instruct
recombin
adenovirus
encod
full
length
protein
aa
sarscov
green
fluoresc
protein
gfp
design
rad
radgfp
respect
construct
describ
previous
use
vitro
express
mammalian
express
plasmid
rad
encod
subunit
aa
subunit
aa
nucleocapsid
n
protein
aa
sarscov
design
pcin
plasmid
radn
rad
respect
construct
describ
previous
recombin
modifi
vaccinia
viru
ankara
rmva
encod
full
length
aa
sarscov
gfp
marker
rmvasgfp
use
vitro
express
kindli
provid
professor
b
moss
nation
institut
allergi
infecti
diseas
nih
usa
note
amino
acid
residu
viral
gene
studi
number
refer
sarscov
strain
two
group
balbc
mice
age
week
immun
intramuscularli
plasmid
dna
lg
per
dose
includ
respect
three
dose
interv
three
week
sixth
week
last
dose
dna
immun
two
group
mice
boost
rad
encod
correspond
antigen
intraperiton
ie
plaqu
form
unit
per
dose
control
group
immun
dose
schedul
except
pcin
radn
use
serum
sampl
mice
group
collect
one
two
three
four
week
rad
booster
antisera
collect
differ
time
point
mice
group
pool
store
use
sarscov
specif
antibodi
titer
collect
antisera
evalu
use
human
antisarscov
antibodi
igg
elisa
kit
beij
huada
gbi
biotechnolog
beij
china
accord
manufactur
instruct
except
hrpconjug
antimous
igg
h
l
zyme
use
secondari
antibodi
total
igg
purifi
collect
antisera
mous
igg
purif
kit
affigel
protein
map
ii
kit
biorad
accord
manufactur
instruct
purifi
igg
quantifi
antimous
igg
assay
plate
becton
dickinson
accord
manufactur
instruct
mous
igg
pharmingen
standard
hrpconjug
antimous
igg
h
l
secondari
antibodi
purifi
igg
sampl
dilut
use
normal
mous
serum
indic
concentr
mgml
neutral
effect
dilut
igg
sampl
evalu
use
viru
neutral
assay
describ
previous
tcid
sarscov
strain
use
well
plate
bind
effici
antibodi
ms
protein
cell
express
ms
protein
cell
prepar
transduc
cell
rad
accord
procedur
describ
chow
et
al
cell
harvest
wash
fac
buffer
phosphatebuff
salin
pb
contain
fetal
bovin
serum
fb
demonstr
ms
protein
bind
abil
antibodi
fac
buffer
contain
purifi
igg
sampl
use
resuspend
kept
ice
min
wash
three
time
icecold
fac
buffer
iggincub
resuspend
goat
antimous
igg
h
l
fitc
zyme
kept
ice
min
mean
fluoresc
intens
mfi
cell
posit
relat
amount
bound
mous
igg
evalu
count
cell
sampl
use
coulter
epic
elit
flow
cytomet
experi
perform
triplic
data
analyz
winmdi
scripp
research
institut
averag
mfi
triplic
present
standard
deviat
sd
compar
ms
bind
effici
igg
serial
antibodi
bind
deplet
assay
carri
assay
approxim
cell
incub
fac
buffer
contain
mgml
purifi
igg
sampl
ice
min
allow
antibodi
bind
antin
igg
bound
cell
design
respect
spun
g
min
deplet
bound
antibodi
liquid
phase
supernat
ie
fac
buffer
contain
unbound
igg
transfer
new
tube
contain
cell
next
round
bind
deplet
condit
concentr
unbound
igg
deplet
round
monitor
analyz
supernat
use
antimous
igg
quantif
assay
describ
igg
bound
cell
pellet
wash
three
time
fac
buffer
analyz
use
flow
cytomet
deplet
round
antibodi
bind
deplet
assay
repeat
time
triplic
averag
mfi
triplic
deplet
round
record
evalu
abil
purifi
igg
sampl
block
ms
protein
bind
cellular
receptor
cellbas
receptor
bind
assay
carri
describ
chou
et
al
modif
briefli
three
type
ligand
cell
prepar
includ
transduc
rad
radgfp
gfp
two
line
cell
infect
rmvasgfp
control
ligand
cell
also
prepar
transduc
radgfp
receptorexpress
cell
ie
vero
monolay
prepar
sixwel
plate
confluenc
purifi
igg
sampl
dilut
fac
buffer
indic
concentr
ligand
cell
preincub
dilut
igg
min
ligand
cell
togeth
igg
sampl
laid
vero
monolay
bind
unbound
ligand
cell
wash
away
accord
procedur
describ
chou
et
al
bound
ligand
vero
cell
detach
trypsin
fix
paraformaldehyd
pb
number
bound
ligand
cell
sampl
count
flow
cytomet
mean
valu
triplic
record
compar
block
effici
igg
use
ligand
cell
block
effici
defin
n
unblock
n
block
n
unblock
n
background
n
block
n
unblock
repres
number
bound
ligand
cell
ie
without
igg
preincub
respect
n
background
number
bound
control
ligand
cell
ie
region
within
proxim
fusion
peptid
chr
subunit
report
contain
neutral
epitop
fig
investig
function
role
epitop
e
coli
express
peptid
cover
region
use
deplet
antibodi
linear
epitop
within
region
purifi
igg
two
region
cover
aa
aa
refer
strain
pcr
amplifi
fuse
use
overlap
extens
pcr
fuse
code
sequenc
design
clone
prseta
invitrogen
sequenc
express
e
coli
strain
invitrogen
accord
manufactur
instruct
express
peptid
affin
purifi
ntermin
fuse
histidin
tag
histag
ni
charg
agaros
millipor
ident
confirm
western
blot
apconjug
antihistag
antibodi
invitrogen
accord
manufactur
instruct
purifi
peptid
incub
igg
mgml
h
igg
bound
peptid
complex
unbound
peptid
remov
use
histag
affin
purif
peptideigg
mixtur
allow
pass
ni
agaros
column
three
time
flowthrough
repres
bound
igg
deplet
igg
design
igg
collect
subject
viru
neutral
igg
quantif
elisa
describ
three
control
deplet
includ
igg
without
addit
peptid
design
igg
mock
deplet
igg
respect
without
addit
peptid
ie
mock
deplet
perform
evalu
specif
deplet
process
possibl
artifact
viru
neutral
specif
bind
igg
peptid
confirm
western
blot
student
ttest
use
compar
signific
specifi
group
p
defin
statist
signific
antibodi
plasmid
dna
prime
viral
vector
boost
immun
regimen
sarscov
specif
antibodi
much
higher
titer
observ
compar
previou
studi
employ
plasmid
dna
immun
mice
immun
recombin
vaccin
encod
subunit
gener
show
higher
neutral
titer
sarscov
antisera
immun
antigen
data
shown
order
quantit
compar
neutral
effici
antibodi
purifi
total
igg
concentr
rang
subject
viru
neutral
assay
neg
control
ie
antin
igg
also
purifi
subject
viru
neutral
assay
show
neutral
effect
test
concentr
neutral
effici
igg
gener
defin
increment
neutral
titer
increas
concentr
igg
simpli
slope
plot
fig
compar
fig
demonstr
igg
neutral
sarscov
wide
rang
concentr
neutral
effici
igg
approxim
time
higher
igg
slop
slop
test
igg
concentr
previou
result
suggest
antibodi
cooper
neutral
sarscov
investig
phenomenon
igg
final
concentr
mgml
subject
neutral
assay
alon
mix
igg
final
concentr
mgml
addit
neutral
effect
ie
enhanc
neutral
titer
igg
ad
observ
igg
concentr
mgml
although
high
concentr
igg
mgml
addit
igg
provid
littl
increas
viru
neutral
titer
fig
present
result
demonstr
igg
abl
neutral
sarscov
differ
effici
addit
neutral
effect
antibodi
observ
rel
low
concentr
bind
effici
antibodi
ms
protein
fig
demonstr
igg
abl
bind
specif
cell
antin
control
igg
show
signific
bind
igg
show
signific
bind
toward
nontransduc
data
shown
demonstr
specif
bind
fig
schemat
diagram
function
domain
region
contain
neutral
epitop
black
box
white
box
black
line
repres
function
domain
region
chosen
studi
design
region
contain
previous
report
neutral
epitop
respect
number
refer
report
neutral
region
list
right
column
fp
nhr
chr
refer
fusion
peptid
ntermin
ctermin
heptad
repeat
transmembran
domain
respect
igg
ms
protein
moreov
bind
capac
ms
protein
toward
igg
ie
amount
igg
bound
ms
protein
substanti
larger
igg
test
concentr
ie
mgml
fig
differenti
bind
igg
ms
demonstr
differ
igg
dosag
bind
effici
ms
ie
increment
mfi
increas
concentr
igg
igg
differ
test
rang
igg
concentr
fig
investig
observ
differ
bind
capac
ms
protein
toward
igg
serial
antibodi
bind
deplet
assay
perform
result
shown
fig
behavior
igg
strikingli
differ
assay
firstli
mfi
cell
drop
start
mfi
first
deplet
round
slowli
decreas
last
deplet
round
consider
decrement
observ
mfi
cell
even
round
deplet
fig
upper
panel
secondli
absolut
amount
unbound
igg
decreas
deplet
round
decrement
unbound
substanti
larger
unbound
igg
deplet
round
fig
lower
panel
also
note
mfi
cell
significantli
lower
cell
deplet
round
absolut
amount
igg
deplet
consider
higher
rate
antin
igg
demonstr
deplet
igg
protein
specif
observ
impli
igg
good
bind
capac
ms
therefor
effici
remov
igg
pool
everi
bindingdeplet
cycl
bind
igg
ms
protein
howev
restrict
henc
dynam
chang
free
igg
differ
antin
igg
process
deplet
character
limit
amount
igg
bound
remov
deplet
cycl
abund
free
igg
sustain
close
valu
mfi
even
mani
round
deplet
receptor
bind
assay
cellbas
receptor
bind
assay
found
igg
also
igg
abolish
bind
ligand
cell
ie
receptor
express
cell
ie
vero
control
antin
igg
fig
sinc
abolit
receptor
bind
ms
protein
igg
report
previous
confirm
phenomenon
repeat
bind
assay
ligand
cell
fig
demonstr
igg
abl
abolish
bind
vero
cell
differ
effici
indic
abolit
receptor
bind
specif
protein
independ
ligand
cell
type
order
quantit
compar
perform
igg
abolit
receptor
bind
block
effici
evalu
wide
rang
igg
concentr
fig
remark
igg
abl
abolish
receptor
bind
rel
low
concentr
mgml
igg
moreov
block
effici
igg
gener
higher
igg
test
concentr
although
igg
show
complet
block
receptor
bind
mgml
fig
data
indic
igg
abl
specif
abolish
bind
ms
protein
receptor
vero
cell
igg
abolish
bind
effici
igg
test
condit
investig
contribut
two
specif
region
subunit
ie
fig
elicit
neutral
antibodi
subunit
express
vivo
antibodi
epitop
igg
deplet
e
coli
express
peptid
cover
region
specif
bind
peptid
igg
demonstr
fig
neutral
titer
igg
found
decreas
significantli
p
variou
peptid
concentr
igg
deplet
demonstr
specif
signific
decreas
neutral
titer
observ
igg
mock
deplet
igg
data
shown
note
antibodi
epitop
undetect
igg
detect
mock
deplet
igg
use
western
blot
data
shown
demonstr
neglig
amount
antibodi
present
igg
addit
accord
igg
quantif
elisa
signific
loss
total
igg
observ
igg
mock
deplet
igg
data
shown
indic
igg
contribut
neglig
fraction
total
igg
popul
although
contribut
significantli
viru
neutral
hand
block
effici
mock
deplet
igg
igg
cellbas
receptor
bind
assay
significantli
differ
data
shown
impli
igg
may
play
major
role
block
receptor
bind
neutral
effect
antibodi
human
anim
cov
well
establish
contribut
antibodi
viru
neutral
remain
controversi
mainli
report
sarscov
even
earlier
studi
fail
prove
antibodi
neutral
effect
independ
antibodi
probabl
due
low
titer
antisera
use
studi
high
titer
antibodi
gener
dnaprimeviralboost
immun
regimen
mice
allow
us
character
role
subunit
viru
dock
viru
neutral
demonstr
igg
abl
neutral
viru
signific
differ
efficaci
fig
compar
quantit
previou
studi
cov
class
viru
fusion
protein
addit
observ
differ
neutral
efficaci
may
account
least
partial
antibodi
bind
ms
assay
fig
show
bind
capac
ms
protein
igg
significantli
larger
igg
low
antibodi
bind
capac
subunit
fig
may
explain
limit
access
surfac
igg
coiledcoil
trimer
structur
form
compact
short
stalk
hide
globular
subunit
radial
cover
oligosaccharid
similar
find
steric
constraint
antibodi
access
anoth
class
viru
fusion
protein
hiv
report
discuss
recent
despit
wide
report
neutral
epitop
within
subunit
role
antibodi
viru
neutral
remain
unknown
base
exist
viral
entri
model
cov
propos
viru
dock
host
cell
surfac
bind
globular
subunit
cellular
receptor
stalklik
subunit
undergo
structur
chang
initi
fusion
viral
envelop
host
cell
membran
allow
migrat
viral
nucleocapsid
cytosol
accord
previou
studi
class
viru
fusion
protein
virus
immedi
receptor
bind
globular
domain
sixhelix
bundl
hr
region
membran
fusion
subunit
ie
subunit
case
sarscov
undergo
dramat
conform
transit
expos
hydrophob
fusion
peptid
mediat
subsequ
viruscel
fusion
howev
evid
report
relat
structur
chang
attach
dock
virus
interestingli
studi
antibodi
demonstr
abl
abolish
bind
protein
host
cell
cellbas
receptor
bind
assay
impli
possibl
involv
subunit
viru
dock
process
unanticip
block
abil
antibodi
argu
current
hypothesi
subunit
particip
membran
fusion
viru
dock
therefor
propos
success
dock
attach
sarscov
may
sole
reli
receptor
bind
subunit
may
also
depend
action
involv
subunit
therefor
block
igg
end
hypothes
two
possibl
mechan
explain
observ
firstli
propos
subunit
may
particip
global
structur
chang
spike
strengthen
bind
enhanc
surfac
complementari
receptor
bind
domain
receptor
altern
speak
bound
antibodi
may
stress
subunit
prevent
receptor
bind
domain
form
complementari
surfac
receptor
secondli
bind
subunit
host
receptor
may
revers
viru
may
fail
stabli
dock
host
cell
surfac
without
subsequ
insert
fusion
peptid
host
cell
membran
one
possibl
explan
simpli
bulki
bound
antibodi
may
hinder
spike
bind
receptor
current
neutral
epitop
subunit
mainli
map
region
proxim
fusion
peptid
chr
fig
addit
neutral
antibodi
target
one
region
found
sera
recov
sar
patient
use
antigen
specif
antibodi
deplet
assay
demonstr
exist
neutral
determin
within
region
deplet
antibodi
region
significantli
diminish
neutral
effect
igg
fig
howev
residu
neutral
effect
igg
impli
region
may
sole
neutral
determin
suggest
presenc
neutral
epitop
within
region
subunit
recent
report
monoclon
neutral
antibodi
target
chr
note
similar
deplet
assay
use
prove
exist
neutral
epitop
beyond
receptor
bind
domain
sar
subunit
furthermor
block
effici
igg
compar
mock
deplet
igg
indic
region
may
involv
viru
dock
altern
speak
neutral
mechan
epitop
may
involv
block
receptor
bind
hand
neutral
epitop
may
expos
conform
chang
protein
trigger
receptor
bind
sinc
bind
igg
ms
nearli
satur
low
rang
igg
concentr
fig
satur
observ
neutral
assay
fig
cellbas
receptor
bind
assay
fig
although
current
neutral
epitop
map
ctermin
tail
subunit
sarscov
neutral
epitop
map
correspond
region
impli
presenc
possibl
function
role
region
defin
function
domain
eg
hr
fusion
peptid
class
viru
fusion
protein
present
experiment
data
suggest
major
neutral
domain
like
receptor
bind
domain
protein
conclus
effici
igg
viru
neutral
protein
bind
block
receptor
bind
compar
quantit
studi
although
igg
neutral
viru
less
effici
compar
igg
sequenc
conserv
subunit
across
variou
strain
includ
sarslik
cov
civet
bat
addit
neutral
effect
antibodi
still
make
candid
develop
recombin
vaccin
neutral
effici
greatli
improv
taken
togeth
result
quantit
comparison
antigen
specif
antibodi
deplet
assay
studi
put
toward
new
understand
function
role
subunit
henc
neutral
mechan
antibodi
would
certainli
provid
valuabl
inform
ration
design
vaccin
antibodi
therapeut
viru
conflict
declar
neutral
titer
deplet
igg
lower
mock
deplet
igg
mgml
result
present
averag
geometr
mean
neutral
titer
three
replic
error
bar
repres
sd
statist
signific
differ
geometr
mean
neutral
titer
igg
mock
deplet
igg
repres
asterisk
p
note
signific
decreas
neutral
titer
observ
igg
mock
deplet
igg
data
shown
